### Check for updates

### OPEN ACCESS

EDITED BY Wenbo Ma, Southern Medical University, China

REVIEWED BY Ivana Šolić, University Hospital Split, Croatia Lei Li, Affiliated Hospital of Jining Medical University, China

\*CORRESPONDENCE Wenmang Xu Mighskysky@126.com

RECEIVED 24 April 2025 ACCEPTED 07 July 2025 PUBLISHED 25 July 2025

#### CITATION

Gao Z, Feng Q, Wang Y, Jiang Y, Han D and Xu W (2025) Case Report: Two cases of bronchiolar adenoma/ciliated muconodular papillary tumor characterized by significant basal cell hyperplasia and squamous metaplasia. *Front. Oncol.* 15:1617720. doi: 10.3389/fonc.2025.1617720

#### COPYRIGHT

© 2025 Gao, Feng, Wang, Jiang, Han and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Case Report: Two cases of bronchiolar adenoma/ciliated muconodular papillary tumor characterized by significant basal cell hyperplasia and squamous metaplasia

Ziran Gao, Qiang Feng, Yuanyuan Wang, Ya Jiang, Dan Han and Wenmang Xu\*

Department of Pathology, 920th Hospital of the Joint Logistics Support Force of Chinese People's Liberation Army, Kunming, Yunnan, China

**Background:** Bronchiolar adenoma/ciliated muconodular papillary tumor (BA/ CMPT) is a rare benign pulmonary tumor from the bronchiolar epithelium. Histologically, it features a continuous basal cell layer and luminal cells. Its resemblance to invasive mucinous adenocarcinoma (IMA) and acinar adenocarcinoma complicates intraoperative frozen section diagnosis. When accompanied by extensive basal cell hyperplasia (BCH) and squamous metaplasia, it may mimic sclerosing pneumocytoma or adenosquamous carcinoma. This study presents two rare BA/CMPT cases with extensive BCH and squamous metaplasia.

**Case presentation:** Case 1: A 62-year-old female was found to have a mixed ground-glass nodule in the right lower lung lobe on CT, raising suspicion of malignancy. She received a thoracoscopic segmentectomy. Histology revealed alveolar epithelial proliferation with extensive BCH and focal squamous metaplasia. Diagnosis: distal-type BA with BCH and squamous metaplasia.Case 2: A 67-year-old female had a solid nodule in the right lower lobe detected by CT, and a thoracoscopic wedge resection was performed. Histopathological examination revealed a lesion composed of ciliated and mucinous luminal cells overlying extensive BCH and areas of squamous metaplasia, with focal atypia observed in the basal cell layer. Diagnosis: proximal-type BA with BCH and atypical squamous metaplasia. IHC demonstrated that luminal cells in both cases expressed TTF-1, while basal cells expressed CK5/6, P63, and P40. Next-generation sequencing (NGS) did not identify any mutations or fusions in common driver oncogenes such as EGFR, BRAF, or KRAS. Postoperative follow-up showed no evidence of tumor recurrence or metastasis in either case.

**Conclusion:** BA with extensive BCH and squamous metaplasia is rare and presents diagnostic challenges due to overlap with conditions such as sclerosing pneumocytoma, adenosquamous papilloma, adenosquamous carcinoma, mucoepidermoid carcinoma, and epithelial-myoepithelial carcinoma. Accurate diagnosis during intraoperative frozen section analysis is crucial for guiding appropriate surgical decision-making. IHC is essential for confirming the diagnosis.

#### KEYWORDS

lung neoplasms, bronchiolar adenoma, ciliated muconodular papillary tumor, immunohistochemistry, basal cell hyperplasia, case report

## **1** Introduction

In 2002, Ishikawa (1) reported a rare pulmonary tumor originating from the bronchial epithelium and named it ciliated muconodular papillary tumor (CMPT), characterized by papillary structures and extracellular mucin deposition. In 2018, Chang et al. (2) expanded the concept by introducing bronchiolar adenoma (BA), defined as a tumor with hyperplastic bronchiolar epithelium and a continuous basal cell layer, identifying CMPT as a subtype of BA. In addition, BA is further classified into proximal-type (predominantly mucous and ciliated luminal cells, resembling bronchiolar epithelium) and distal-type (mainly type II pneumocytes or Clara cells with fewer mucous and ciliated cells, resembling terminal or respiratory bronchiolar epithelium) (2-5). Due to its histological resemblance to malignancies such as invasive mucinous adenocarcinoma (IMA) and acinar adenocarcinoma, BA faces significant challenges in diagnosis, especially during intraoperative frozen section analysis, where identifying the basal cell layer is difficult and may lead to misdiagnosis and overtreatment. This study reports two rare cases of BA with extensive BCH and squamous metaplasia, including one with atypical features. This study combines findings from the literature with clinical, histological, immunohistochemical, and molecular analyses, aiming to enhance diagnostic accuracy and guide optimal surgical decision-making.

### 2 Case description: case 1

A 62-year-old female patient was admitted for lower back pain without symptoms of cough, sputum production, or chest tightness. She had no history of lung cancer, tuberculosis, or other major pulmonary diseases. Serum tumor markers (CEA, CYFRA21-1, SCCA, NSE, ProGRP) were within normal limits. Chest CT revealed a  $14 \times 11$  mm mixed ground-glass nodule located in the posterior basal segment of the right lower lung lobe. The lesion exhibited well-defined borders, vascular penetration, and signs of pleural indentation, with no evidence of hilar or mediastinal lymphadenopathy (Figures 1A, B). Following evaluation, she received a thoracoscopic segmentectomy of the right lower lung lobe with an intraoperative frozen section diagnosis.

During surgery, an 80 mm  $\times$  45 mm  $\times$  10 mm specimen from the right lower lung lobe was examined. A gray-red, ill-defined lesion measuring 14  $\times$  8  $\times$  3 mm was identified approximately 10 mm from the pleura. Intraoperative frozen section analysis revealed nests and cords of uniform tumor cells growing along the alveolar stroma, with bland cytomorphology. The lesion was diagnosed as a benign lesion or a low-grade malignant. Based on these findings, mediastinal lymphadenectomy (station 9) was performed. Postoperative pathology showed no tumor metastasis.

Microscopy showed the tumor had ill-defined borders with surrounding lung tissue and was interspersed with bronchioles and thick-walled vessels (Figures 2A, B). At low magnification, glandular, papillary, and solid growth patterns were observed, with foamy macrophages in alveolar spaces. High-power views revealed adenoid and papillary areas composed of luminal and basal cells. Luminal cells were cuboidal, low columnar, or peg-shaped, with focal ciliation. Basal cells showed extensive hyperplasia with bland features, eosinophilic or clear cytoplasm, oval nuclei, fine chromatin, and absent mitoses (Figure 2C). Solid areas showed nests or sheets of basal cells without atypia and focal squamous metaplasia. Scattered tubules or incomplete glands lined by flattened epithelial cells were also noted (Figures 2D-F). Immunohistochemistry showed luminal cells positive for CK7, TTF-1, and Napsin A but negative for CK5/6, P40, and P63 (Figure 2G). Basal cells expressed CK5/6, P40, and P63, and were negative for TTF-1, BRAF, S-100, SMA, EMA, PR, SSTR-2, CD56, CgA, and Syn. The Ki-67 index in basal cells was ~1% (Figures 2G, I). DNA/RNA sequencing revealed no mutations or fusions in EGFR, ALK, ROS1, BRAF, KRAS, or other driver genes. The final diagnosis was distal-type bronchiolar adenoma with basal cell hyperplasia and squamous metaplasia. The patient recovered uneventfully, with no recurrence or metastasis after 16 months of follow-up. The clinicopathological features of the patient are summarized in Table 1, and the diagnostic and treatment timeline is illustrated in Figure 3.



FIGURE 1

Chest CT of Case 1 shows a  $14 \times 11$  mm pure ground-glass nodule (red arrow) in the posterior basal segment of the right lower lobe, with well-defined borders, vascular penetration, and pleural indentation [(A) axial; (B) coronal]. In Case 2, a solid  $11 \times 8$  mm nodule (red arrow) is seen in the outer basal segment of the right lower lobe, featuring lobulation, vacuoles, and dilated draining veins [(C) axial; (D) coronal].

# 3 Case description: case 2

A 67-year-old female was admitted for abdominal pain with no symptoms of cough, sputum production, or chest tightness. She had no history of major pulmonary diseases, and serum tumor markers were normal. Chest CT showed an  $11 \times 8$  mm solid nodule in the outer basal segment of the right lower lung lobe, showing lobulation, vacuolar signs, and dilated draining veins. No enlarged lymph nodes were observed in the hilar or mediastinal regions (Figures 1C, D). Following evaluation, she underwent thoracoscopic wedge resection with intraoperative frozen section analysis.

The wedge-resected specimen measured 75 mm  $\times$  25 mm  $\times$  18 mm. A gray-white nodule (11 mm) adjacent to the pleura was noted, with no capsule and a solid, mucoid cut surface. Intraoperative frozen section analysis revealed ciliated luminal cells, mucous cells, and extensively hyperplastic basal cells with squamous metaplasia. Some areas exhibited cord-like basal cell growth with atypia and focal invasion through the basement membrane (Figure 4F). The intraoperative frozen section diagnosis suggested BA with BCH, squamous metaplasia, and atypical hyperplasia, with paraffin section evaluation required to exclude malignancy. Based on these findings, mediastinal lymphadenectomy (station 7) was performed, and postoperative pathological examination confirmed no evidence of metastasis.

Microscopy revealed a well-demarcated lesion with glandular and papillary growth, lacking a fibrous capsule, and traversed by thick-walled vessels. Mucin deposits and macrophages were abundant in both the tumor and surrounding alveoli, accompanied by stromal lymphocytic infiltration and the formation of lymphoid follicles (Figures 4A-C). The tumor exhibited a bi-layered structure of ciliated and mucous luminal cells overlying hyperplastic basal cells with squamous metaplasia. Basal cells formed palisading arrangements around glandular lumina, showing eosinophilic cytoplasm, oval nuclei, fine chromatin, and prominent nucleoli, with interspersed neutrophils (Figure 4D). Focal squamous metaplasia of the basal cells exhibited disorganized arrangement, irregular borders, enlarged nuclei, coarse chromatin, and occasional mitotic figures, indication cytological atypia (Figure 4E). IHC indicated that luminal cells were positive for CK7, TTF-1, and Napsin A, while basal cells expressed CK5/6, P40, and P63, with weak TTF-1 expression (Figures 4G, H). Approximately 20% of basal cells were positive for the Ki-67 proliferation index, and P53 exhibited variable nuclear expression in 20% of basal cells (Figure 4I). NGS revealed no mutations or fusions. The final diagnosis was proximal-type BA with BCH, squamous metaplasia, and focal atypical squamous metaplasia. The patient recovered well postoperatively, with no recurrence or metastasis at the 9-month follow-up. We recommend that both patients undergo chest CT scans at 1 month and 6 months postoperatively. If no abnormalities are detected and the condition remains stable, annual follow-up imaging is advised through the fifth postoperative year. The clinicopathological features of the patient are summarized in Table 1, and the diagnostic and treatment timeline is illustrated in Figure 3.



#### FIGURE 2

Histopathological and immunohistochemical findings in Case 1. (A) The tumor shows indistinct borders with surrounding lung tissue (H&E, magnification ×10). (B) Bronchioles and thick-walled blood vessels are observed within the tumor (H&E, magnification ×40). (C) In glandular and papillary regions, luminal cells (blue arrows) appear cuboidal, low columnar, or hobnail-shaped, with extensive BCH (red arrows) and foamy macrophages in alveolar spaces (H&E, magnification ×100). (D) In solid areas, basal cells form nests or sheets, exhibiting bland cytomorphology with eosinophilic or clear cytoplasm (H&E, magnification ×200). (E) In the focal area, luminal cells consist of columnar ciliated cells (red arrows) and flattened epithelial cells (blue arrows) (H&E, magnification ×200). (F) BCH with squamous metaplasia is evident, including visible intercellular bridges (H&E, magnification ×400). (G) Luminal cells express TTF-1, while hyperplastic basal cells are negative (magnification ×200). (H) Basal cells demonstrate diffuse expression of P40 (IHC, magnification ×200). (I) The Ki-67 proliferation index in hyperplastic basal cells is approximately 1% (IHC. magnification ×200).

# 4 Discussion

BA/CMPT is a newly recognized and rare benign tumor included in the 5th edition of the WHO thoracic tumor classification (ICD-O code 8140/0) (6). It typically affects middleaged to elderly individuals (age range: 19-84 years; mean: 68), with no sex predilection or clear association with smoking (5, 7, 8). Most cases are asymptomatic and detected incidentally during routine check-ups or unrelated evaluations (9, 10). Surgical resection is the preferred treatment for BA/CMPT, with an excellent prognosis and no reported recurrences or metastases. Since BA/CMPT typically occurs in the peripheral lung and exhibits low malignant potential, wedge resection is generally sufficient, and excessive resection and systematic lymph node sampling are unnecessary (7). This study reports two cases of incidentally detected BA/CMPT in elderly, non-smoking women who were asymptomatic and showed no abnormal serum tumor markers or lab results. Both patients underwent surgery, and follow-up revealed no recurrence or metastasis, consistent with previous reports.

BA/CMPT can occur in any lung lobe, but most often occurs in the right lower lobe, typically as a solitary, peripheral, or subpleural lesion (3, 11). Tumors range from 3.0 mm to 45 mm, mostly less than 20 mm in diameter (3, 12). CT imaging commonly shows pure or mixed ground-glass opacities or solid nodules, sometimes with cystic or cavitary features. Typical features include lobulation, vacuolar signs, vascular convergence, and spiculations, while calcifications are rare (13, 14). A slow-growing, subpleural nodule with vacuolar and vascular signs should raise suspicion for BA/ CMPT (15). Proximal-type BA often appears as mucin-rich solid nodules with vacuolar signs, while distal-type BA presents as ground-glass nodules with solid components (14). However, these features are not specific to BA/CMPT and may overlap with other benign or malignant lung tumors. In this study, Case 1 shows a 14 mm distal-type BA in the posterior basal segment of the right lower lobe, appearing as a mixed ground-glass nodule with vascular penetration and pleural indentation, suggesting a high-risk lesion. Case 2 shows an 11 mm proximal-type BA in the outer basal segment of the right lower lobe, appearing as a solid nodule with

TABLE 1	Clinicopathological	features	of	two	patients
---------	---------------------	----------	----	-----	----------

Feature	Case 1	Case 2	
Age/sex	62/Female	67/Female	
Location	Right lower lobe	Right lower lobe	
Size (mm)	14	11	
CT findings	Pure ground-glass nodules, with clear boundaries, vascular invasion and pleural retraction signs.	Solid nodules with lobulated appearance, vacuolar signs, and thickened draining veins.	
Treatment	Segmentectomy + mediastinal lymphadenectomy (station 9).	Wedge resection + mediastinal lymphadenectomy (station 7).	
Pathological features	Ill-defined borders; glandular, papillary, and solid patterns. Luminal cells cuboidal to low columnar with focal ciliation. BCH with bland cytology.	Well-demarcated lesion with glandular and papillary growth. Luminal cells ciliated and mucinous. Basal cells with squamous metaplasia and focal atypia.	
Immunohistochemical staining	Luminal cells: CK7 <sup>+</sup> , TTF-1 <sup>+</sup> , Napsin A <sup>+</sup> ; CK5/6 <sup>-</sup> , P40 <sup>-</sup> , P63 <sup>-</sup> , Basal cells: CK5/6 <sup>+</sup> , P40 <sup>+</sup> , P63 <sup>+</sup> ; TTF-1 <sup>-</sup> , BRAF <sup>-</sup> , S- 100 <sup>-</sup> , PR <sup>-</sup> , CgA <sup>-</sup> , Syn <sup>-</sup> . Ki-67 ~ 1%.	Luminal cells: CK7 <sup>+</sup> , TTF-1 <sup>+</sup> , Napsin A <sup>+</sup> . Basal cells: CK5/6 <sup>+</sup> , P40 <sup>+</sup> , P63 <sup>+</sup> , weak TTF-1 <sup>+</sup> . Ki-67 $\approx$ 20%.	
Gene alteration	None	None	
Outcome	No recurrence/metastasis at 16-month follow-up.	No recurrence/metastasis at 9-month follow-up.	

lobulation, vacuolar signs, and vascular convergence. PET-CT or biopsy is advised. These cases highlight the imaging variability of BA/CMPT and the diagnostic challenge it presents.

Grossly, BA/CMPT is well-demarcated from surrounding lung tissue, lacks a distinct capsule, and exhibits a gray-white to gray-red, soft, solid cut surface, sometimes with a mucoid texture (16, 17). Histologically, it features diverse patterns-papillary, glandular, or flat-along with a characteristic bilayer structure composed of basal cells and luminal cells (ciliated, mucinous, or alveolar epithelial) (2, 6, 18). Bronchioles and thick-walled vessels are frequently observed within or near the tumor (19). The continuous basal cell layer and a bi-layered structure are critical for diagnosis. In typical cases with clear ciliated or mucinous cells, diagnosis is straightforward. However, in distal-type BA, where luminal cells are cuboidal or low columnar, IHC is often required to confirm the basal cell layer and cellular composition. Intraoperative frozen section diagnosis can be challenging due to the difficulty in identifying the bi-layered structure and ciliated cells, thus leading to potential misdiagnosis as malignant tumors. Immunohistochemical markers, such as TTF-1, Napsin A, CK5/6, p40, and Ki-67, are valuable tools for diagnosis: TTF-1 is expressed in basal and luminal cells but negative in mucinous and ciliated cells; CK5/6, p40, and p63 are strongly expressed in basal cells; and Ki-67 shows low proliferative activity (2, 19, 20).

The two cases reported here exhibit significant histological differences from classic BA/CMPT, characterized by extensive BCH and squamous metaplasia, which are rare findings. Although focal areas of BCH and squamous metaplasia have been occasionally observed in BA/CMPT, particularly in proximal-type lesions, cases exhibiting such widespread changes remain rare (9). Teng et al. (21) reported five cases of BA with BCH and squamous metaplasia, where most luminal cells were columnar with rare ciliated cells and lacked mucinous cells. The hyperplastic basal cells showed bland cytomorphology and a low Ki-67 proliferation index (<5%), resembling the features of Case 1 (distal-type BA). It is worth noting that both Case 1 and the 5 cases reported by Teng et al. (21) demonstrate negativity for TTF-1 in hyperplastic basal cells, which deviates from the typical immunophenotype of BA/CMPT. Sun et al. (7) reported a case of proximal-type BA/CMPT with squamous metaplasia exhibiting severe atypia and tumor budding, suggesting potential malignant transformation into squamous cell carcinoma. A similar pattern was observed in Case 2, which exhibited disorganized squamous cells, cytological atypia, and an elevated Ki-67 proliferation index. Wang et al. (22) found that all four proximal-type BA cases in their study displayed BCH or squamous metaplasia, including one with atypical squamous hyperplasia, whereas distal-type cases lacked these features. Additionally, Miyai et al. (23) reported a CMPT case progressing to squamous cell carcinoma. These findings suggest that proximal-type BA is more prone to BCH and squamous metaplasia compared to distal-type BA. The presence of atypical squamous changes requires thorough sampling and careful examination to rule out malignancy and avoid missed diagnosis.

In Case 1, the tumor displayed glandular, papillary, and solid nested growth patterns. The luminal cells ranged from cuboidal to low columnar in shape and were accompanied by extensive BCH characterized by bland cytomorphology, finely granular chromatin, and abundant cytoplasm. Histologically, Case 1 overlapped with sclerosing pneumocytoma, epithelial-myoepithelial carcinoma, carcinoid tumors, and primary pulmonary meningioma. Thus, differential diagnosis relied on IHC. Sclerosing pneumocytoma was excluded due to its expression of vimentin and absence of P40/P63, which contrasted with the case of BA/CMPT (24). Epithelialmyoepithelial carcinoma shares a bi-layered structure with BA/ CMPT, featuring peripheral myoepithelial cells that are spindleshaped or oval with clear or eosinophilic cytoplasm, making the two morphologically similar. However, the myoepithelial cells for epithelial-myoepithelial carcinoma express CK5/6, P63, P40, S-100, and SMA but lack TTF-1 expression, whereas hyperplastic basal cells in BA/CMPT typically express TTF-1 (25, 26). In this case, the hyperplastic basal cells were negative for TTF-1 but positive for CK5/ 6, P63, and P40 (myoepithelial markers), creating significant overlap in morphology and immunohistochemical results that can lead to diagnostic confusion. Carcinoid tumors were excluded due to the absence of neuroendocrine markers (CD56, CgA, Syn) in the basal cells of BA/CMPT (27). Similarly, primary pulmonary meningiomas were excluded as their tumor cells express SSTR-2, PR, and vimentin but lack P63, P40, and TTF-1 expression (28).

In Case 2, the tumor demonstrated extensive BCH, squamous metaplasia, and a papillary growth pattern, closely resembling mixed





### FIGURE 4

Histopathological and immunohistochemical findings in Case 2. (A) The tumor is well-demarcated from surrounding lung tissue and lacks a fibrous capsule (H&E, magnification ×10). (B) Abundant mucus (red arrows) and macrophages are observed within the tumor and surrounding alveolar spaces (H&E, magnification ×100). (C) Prominent stromal lymphocytic infiltration with lymphoid follicle formation (red arrows) and extensive basal cell proliferation (H&E, magnification ×100). (D) Luminal cells consist of ciliated cells (red arrows) and mucous cells (blue arrows), with extensively hyperplastic basal cells exhibiting squamous metaplasia arranged in a palisading pattern around glandular lumina (H&E, magnification ×400). (E) Focal areas exhibit disorganized basal cells with squamous metaplasia, enlarged nuclei, coarse chromatin, and cytological atypia (H&E, magnification ×400). (F) The intraoperative frozen section reveals basal cells forming disorganized cords, suggesting possible basement membrane invasion, with dense interstitial lymphocytic infiltration (H&E, magnification ×200). (G) Luminal cells strongly expressed TTF-1, while basal cells demonstrate weak expression (IHC, magnification x200). (H) Basal cells exhibit diffuse expression of P40 (IHC, magnification x200). (I) In hotspot areas, the Ki-67 proliferation index in basal cells reaches approximately 20% (IHC, magnification x200).

10.3389/fonc.2025.1617720

squamous cell and glandular papilloma (MSGP) in both morphology and immunophenotype. Both tumors express TTF-1, P63, and P40, making differentiation difficult, especially when squamous metaplasia is prominent. However, MSGP typically presents as a symptomatic polypoid lesion located in the proximal bronchi (29, 30), whereas BA/ CMPT usually arises in the peripheral lung and is often asymptomatic, most commonly detected incidentally on imaging. In this case, the tumor was mucus-filled and composed of abundant mucinous cells and basal cells with squamous metaplasia. Focal squamous epithelial cells exhibited atypia. Extensive sampling or complete tumor excision is crucial to exclude malignant transformation into squamous cell carcinoma. Differential diagnosis includes adenosquamous carcinoma and well-differentiated mucoepidermoid carcinoma. Adenosquamous carcinoma is a bi-layered tumor composed of components from both adenocarcinoma and squamous cell carcinoma. The adenocarcinoma component may exhibit any histological subtype, while the squamous component can be either keratinizing or non-keratinizing. When composed of mucinous adenocarcinoma and non-keratinizing squamous cell carcinoma, the morphology may resemble that of Case 2. However, adenosquamous carcinoma typically shows significant cytologic atypia and stromal invasion. Well-differentiated mucoepidermoid carcinoma comprises mucinous cells, intermediate cells, and squamous cells, with a cellular composition and morphology similar to Case 2. However, it demonstrates invasive growth into surrounding tissues, the intermediate and squamous cells are negative for TTF-1, and the tumor is commonly associated with MAML2 rearrangements (31).

Multiple driver gene alterations have been identified in BA/ CMPT, including mutations in BRAF, EGFR, AKT1, KRAS, and ALK rearrangements (2, 32-34). These alternations support classifying BA/CMPT as a neoplastic disease rather than a reactive or metaplastic lesion. Unlike lung adenocarcinoma, which frequently harbors EGFR mutations, the most common genetic alteration in BA/ CMPT is the BRAF V600E mutation, detected in approximately 50% of reported cases (35). EGFR mutations are primarily exon 19 deletions, with occasional reports of exon 20 insertions (36). Teng et al. (21) reported BRAF V600E mutations in all five BA cases with BCH and squamous metaplasia, confirmed by BRAF immunostaining in hyperplastic basal cells, suggesting a role in tumor progression. Wang et al. (22) reported EGFR exon 19 deletions in two of four BA/ CMPT cases with BCH or squamous metaplasia and BRAF V600E mutation in one case. In contrast, Sun et al. (7) reported no hotspot mutations in a BA/CMPT case with squamous metaplasia. In this study, NGS of both cases revealed no mutations or fusions in BRAF, EGFR, AKT1, or 17 other tumor-related genes. These findings suggest that the relationship between BCH/squamous metaplasia in BA/ CMPT and mutations or fusions of driver genes remains unclear and requires further investigation with more case data.

In recent years, an increasing number of studies have reported malignant transformation in BA/CMPT. Chen et al. (37), Han et al. (38), Liu et al. (39), and Yang et al. (40) each reported BA case with partial or loss of the basal cell layer, showing progression to IMA. Miyai et al. (23) reported CMPT transformation into squamous cell carcinoma, while wang et al. (41) documented a BA case with features of invasive adenocarcinoma at the tumor margins, including basal cell

loss, cellular atypia, and stromal invasive reactions. Zhao et al. (42) described three BA cases with peripheral glandular components lacking basal cells, demonstrating transitions from bilayered to atypical monolayered structures, along with prominent stromal fibrosis. One of these cases harbored EGFR mutations in both the preserved and atypical regions, supporting the hypothesis of malignant potential. Importantly, although previous studies have reported the potential for malignant transformation, no malignant features were observed in the present cases. Since BA was first defined in 2018, no cases of recurrence or metastasis have been reported, and the tumor is generally considered to exhibit indolent biological behavior. Sato et al. (43) proposed that CMPT is a well-differentiated pulmonary tumor with malignant potential, although it has ciliated epithelial cells. While BA/CMPT is largely considered benign, its malignant potential remains inconclusive and requires further investigation through case studies and long-term follow-up to better understand its biological behavior. Currently, no standardized follow-up duration is recommended. However, for patients who have undergone complete resection, a 5-year follow-up seems to be sufficiently safe (7).

# 5 Conclusion

BA/CMPT is a rare benign pulmonary tumor originating from the bronchiolar epithelium, characterized by a bi-layered structure consisting of proliferative bronchiolar epithelium and a continuous basal cell layer. Proximal-type BA with extensive BCH can mimic sclerosing pneumocytoma, epithelial-myoepithelial carcinoma, carcinoid tumors, and meningiomas, while distal-type BA with extensive BCH and squamous metaplasia must be differentiated from adenosquamous papilloma, adenosquamous carcinoma, and well-differentiated mucoepidermoid carcinoma. Accurate diagnosis requires integrating clinical, radiological, and immunohistochemical data. Improving the awareness of pathologists regarding the unique histological subtypes of this tumor is essential to minimize misdiagnoses during frozen section evaluations and to avoid unnecessary surgical over-resection.

# Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

# **Ethics statement**

The studies involving humans were approved by the Ethics Committee of 920th Hospital of Joint Logistics Support Force, PLA. The studies were conducted in accordance with the local legislation and institutional requirements. The human samples used in this study were acquired from primarily isolated as part of your previous study for which ethical approval was obtained. Written informed consent for participation was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and institutional requirements. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

## Author contributions

ZG: Data curation, Writing – original draft, Writing – review & editing, Investigation, Conceptualization, Resources. QF: Resources, Funding acquisition, Data curation, Conceptualization, Methodology, Writing – original draft, Investigation. YW: Writing – original draft, Data curation, Investigation, Conceptualization. YJ: Resources, Investigation, Data curation, Writing – review & editing, Methodology. DH: Data curation, Writing – original draft, Conceptualization, Investigation. WX: Methodology, Writing – review & editing, Conceptualization, Writing – original draft, Resources.

# Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by Joint Projects of Applied Basic Research of Kunming Medical University and Yunnan Province Department of Science and Technology (202301AY070001-021, 202301AY070001-244).

### References

1. Ishikawa Y. Ciliated muconodular papillary tumor of the peripheral lung: benign or Malignant. *Pathol Clin Med.* (2002) 20:964–5.

2. Chang JC, Montecalvo J, Borsu L, Lu S, Larsen BT, Wallace WD, et al. Bronchiolar adenoma: expansion of the concept of ciliated muconodular papillary tumors with proposal for revised terminology based on morphologic, immunophenotypic, and genomic analysis of 25 cases. *Am J Surg Pathol.* (2018) 42:1010–26. doi: 10.1097/PAS.00000000001086

3. Wang Y, Wang D, Wang J, Zhao S, Ren D, Chen G, et al. Primary ciliated muconodular papillary tumor: a rare pulmonary disease and literature review of 65 cases. *Thorac Cancer.* (2021) 12:1917–22. doi: 10.1111/1759-7714.13963

4. Zhang SB, Liu XH, Zhang XX, Zhang P, Feng HM, Jiang P. Bronchiolar adenoma with EGFR exon 19 deletion mutation: a case report and literature review. *Front Oncol.* (2025) 15:1565549. doi: 10.3389/fonc.2025.1565549

5. Kao TH, Yeh YC. Ciliated muconodular papillary tumor/bronchiolar adenoma of the lung. Semin Diagn Pathol. (2021) 38:62–71. doi: 10.1053/j.semdp.2021.04.002

6. Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. *J Thorac Oncol.* (2022) 17:362–87. doi: 10.1016/j.jtho.2021.11.003

7. Sun J, Zhao W, Zhang C, Zheng E, Jiang X, Wang L, et al. Multiple bronchiolar adenomas/ciliated muconodular papillary tumors of the bilateral lung with tumor budding and potential Malignant transformation into squamous cell carcinoma: a case report and literature review. *Trans Lung Cancer Res.* (2023) 12:1611–24. doi: 10.21037/ttcr-23-374

8. Çağan P, Kimiaei A, Safaei S, Youcefi HE, Abu Saadeh A, Yaman F, et al. Bronchiolar adenoma/ciliated muconodular papillary tumor complicated by lymphoid interstitial pneumonia in a patient with Sjögren's disease: A case report and systematic review. *Thorac Cancer*. (2024) 15:1975–88. doi: 10.1111/1759-7714.15420

9. Gao H, Du XL, Chen CN, Song GX, Gu YL, Li HX. Bronchiolar adenoma: a clinicopathological analysis of 15 cases. *Zhonghua Bing li xue za zhi*. (2020) 49:556–61. doi: 10.3760/cma.j.cn112151-20191125-00755

# Acknowledgments

We thank Ms. Lilin Yang (Department of Pathology, 920th Hospital of the Joint Logistics Support Force of PLA, Kunming, Yunnan, China) for her assistance with the IHC techniques.

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# **Generative AI statement**

The author(s) declare that no Generative AI was used in the creation of this manuscript.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

10. Sun J, Liu K, Tong H, Liu H, Li X, Luo Y, et al. CT texture analysis for differentiating bronchiolar adenoma, adenocarcinoma in *situ*, and minimally invasive adenocarcinoma of the lung. *Front Oncol.* (2021) 11:634564. doi: 10.3389/ fonc.2021.634564

11. Ding B, Shang Z, Xiang Z, Han Y. Clinicopathologic features and frozen diagnostic pitfalls of bronchiolar adenoma/ciliated muconodular papillary tumors (BA/CMPTs). *Am J Surg Pathol.* (2023) 47:431-9. doi: 10.1097/PAS.00000000002016

12. Onishi Y, Kusumoto M, Motoi N, Watanabe H, Watanabe SI. Ciliated muconodular papillary tumor of the lung: thin-section CT findings of 16 cases. *Am J Roentgenology.* (2020) 214:761–5. doi: 10.2214/AJR.19.21945

13. Yang Y, Xie X, Jiang G, Zhang L, Liu H. Clinicopathological characteristic of ciliated muconodular papillary tumor of the lung. *J Clin Pathol.* (2022) 75:128–32. doi: 10.1136/jclinpath-2020-207205

14. Liu X, Xu Y, Wang G, Ma X, Lin M, Zuo Y, et al. Bronchiolar adenoma/ ciliated muconodular papillary tumor: advancing clinical, pathological, and imaging insights for future perspectives. *Clin Radiol.* (2024) 79:85–93. doi: 10.1016/ j.crad.2023.10.038

15. Kamata T, Yoshida A, Kosuge T, Watanabe SI, Asamura H, Tsuta K. Ciliated muconodular papillary tumors of the lung: a clinicopathologic analysis of 10 cases. *Am J Surg Pathol.* (2015) 39:753–60. doi: 10.1097/PAS.00000000000414

16. Taguchi R, Higuchi K, Sudo M, Misawa K, Miyamoto T, Mishima O, et al. A case of anaplastic lymphoma kinase (ALK)-positive ciliated muconodular papillary tumor (CMPT) of the lung. *Pathol Int.* (2017) 67:99–104. doi: 10.1111/pin.12504

17. Kataoka T, Okudela K, Matsumura M, Mitsui H, Suzuki T, Koike C, et al. A molecular pathological study of four cases of ciliated muconodular papillary tumors of the lung. *Pathol Int.* (2018) 68:353–8. doi: 10.1111/pin.12664

18. Bo J, Chen X, Zhang T, Zhu X, Zhang L, Liu Y, et al. Clinicopathological features and genomic analysis of bronchiolar adenoma. *Histol Histopathol.* (2023) 38:1465–74. doi: 10.14670/HH-18-609

19. Qiu Y, Zhang NC, Liu LL, Tan X, Jin N, He H, et al. Bronchiolar adenoma: a clinicopathological analysis of 12 cases. *Zhonghua bing li xue za zhi*. (2021) 50:937–9. doi: 10.3760/cma.j.cn112151-20201225-00967

20. Zhu M, Yang Q, Zhan S, Liu W, Liu W, Guo L, et al. Clinicopathological analysis of bronchiolar adenoma combined with lung adenocarcinoma: Report of eight cases and literature review. *Histol Histopathol.* (2024) 39:783–94. doi: 10.14670/HH-18-682

21. Teng X, Chen Z, Zhang L, Teng X. Bronchiolar adenoma with squamous metaplasia: a distinct phenotype. *Histopathology.* (2023) 83:193–201. doi: 10.1111/his.14907

22. Wang B, Yang L, Lin J, Wang Y, Wang SM, Zhong DR. Clinicopathological features of bronchiolar adenoma versus mixed squamous cell and glandular papilloma: a comparative analysis. *Zhonghua Bing li xue za zhi.* (2021) 50:458–64. doi: 10.3760/cma.j.cn112151-20201006-00761

23. Miyai K, Takeo H, Nakayama T, Obara K, Aida S, Sato K, et al. Invasive form of ciliated muconodular papillary tumor of the lung: A case report and review of the literature. *Pathol Int.* (2018) 68:530–5. doi: 10.1111/pin.12708

24. Si QQ, Han J, Gao XZ, Zang YY, Wang TL, Li SL. Histopathological diagnosis of pulmonary sclerosing pneumocytoma in needle biopsy specimens. *Zhonghua bing li xue za zhi*. (2024) 53:1105–10. doi: 10.3760/cma.j.cn112151-20240403-00218

25. Sharma S, Tayal A, Khatri S, Mohapatra SG, Mohanty SK. Primary pulmonary epithelial-myoepithelial carcinoma: Report of a rare and under-diagnosed low-grade Malignancy. J Cancer Res Ther. (2022) 18:795–800. doi: 10.4103/jcrt.JCRT\_559\_20

26. Morgado S, Santos AF, Nogueira F. Primary pulmonary epithelial-myoepithelial carcinoma: A case report and comprehensive literature review of a rare lung neoplasm. *Cureus*. (2025) 17:e80188. doi: 10.7759/cureus.80188

27. Centonze G, Maisonneuve P, Simbolo M, Lagano V, Grillo F, Fabbri A, et al. Lung carcinoid tumors: histology and Ki-67, the eternal rivalry. *Histopathology*. (2023) 82:324–39. doi: 10.1111/his.14819

28. Zhang DB, Chen T. Primary pulmonary meningioma: a case report and review of the literature. *World J Clin cases.* (2022) 10:4196–206. doi: 10.12998/wjcc.v10.i13.4196

29. Wang B, Yang I, Lin J, Wang Y, Wang SM, Zhong DR. Clinicopathological features of bronchiolar adenoma versus mixed squamous cell and glandular papilloma: a comparative analysis. *Zhonghua Bing li xue za zhi= Chin J Pathol.* (2021) 50:458–64. doi: 10.3760/cma.j.cn112151-20201006-00761

30. Saraya T, Fujiwara M, Kimura H, Takei H, Takizawa H. A 17-year-old woman with a solitary, mixed squamous cell and glandular papilloma of the bronchus. *Respirology Case Rep.* (2019) 7:e00393. doi: 10.1002/rcr2.393

31. Shen W, Yang T, Fan Y, Li X, Ai C, Wang X, et al. Pulmonary mucoepidermoid carcinoma: A clinicopathological study of 45 patients. *Thorac Cancer*. (2022) 13:2385–9. doi: 10.1111/1759-7714.14536

32. Kamata T, Sunami K, Yoshida A, Shiraishi K, Furuta K, Shimada Y, et al. Frequent BRAF or EGFR mutations in ciliated muconodular papillary tumors of the lung. J Thorac Oncol. (2016) 11:261–5. doi: 10.1016/j.jtho.2015.10.021

33. Udo E, Furusato B, Sakai K, Prentice LM, Tanaka T, Kitamura Y, et al. Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT 1 mutation. *Diagn Pathol.* (2017) 12:62. doi: 10.1186/s13000-017-0651-2

34. Shao J, Yin JC, Bao H, Zhao R, Han Y, Zhu L, et al. Morphological, immunohistochemical, and genetic analyses of bronchiolar adenoma and its putative variants. *J Pathology: Clin Res.* (2021) 7:287–300. doi: 10.1002/cjp2.197

35. Higashiyama M, Motoi N, Yotsukura M, Yoshida Y, Nakagawa K, Yagishita S, et al. Clinicopathological characteristics and molecular analysis of lung cancer associated with ciliated muconodular papillary tumor/bronchiolar adenoma. *Pathol Int.* (2023) 73:188–97. doi: 10.1111/pin.13316

36. Yang C, Wang X, Da J, Ma K. Distal-type bronchiolar adenoma of the lung harboring an EGFR exon 21 p. *L858R mutation: A Case Rep Thorac Cancer*. (2020) 11:3596–8. doi: 10.1111/1759-7714.13692

37. Chen F, Ren F, Zhao H, Xu X, Chen J. Mucinous adenocarcinoma caused by cancerization from a ciliated multinodular papilloma tumor: A case report. *Thorac Cancer*. (2021) 12:1629–33. doi: 10.1111/1759-7714.13956

38. Han X, Hao J, Ding S, Wang EH, Wang L. Bronchiolar adenoma transforming to invasive mucinous adenocarcinoma: a case report. *OncoTargets Ther.* (2021) 14:2241–6. doi: 10.2147/OTT.S299864

39. Liu XL, Miao CF, Li M, Li P. Malignant transformation of pulmonary bronchiolar adenoma into mucinous adenocarcinoma: a case report. *World J Clin cases.* (2023) 11:233–41. doi: 10.12998/wjcc.v11.i1.233

40. Yang YH, Yin K, Xu JQ, Xu XY, Zhang JL, Liu JX, et al. Proximal bronchiolar adenoma with Malignant transformation to invasive mucinous adenocarcinoma with 4 years follow-up: a case report and literature review. *Front Oncol.* (2025) 15:1491339. doi: 10.3389/fonc.2025.1491339

41. Wang F, Shen MH, Cao D, Lv JH. Malignant ciliated muconodular papillary tumors of the lung: a case report. *Int J Surg Pathol.* (2021) 29:520–3. doi: 10.1177/1066896920988359

42. Zhao J, Zhang JW, Jiang T, Yu SJ, Xiong DT, Lu YF, et al. Bronchiolar adenoma with atypical and Malignant components: clinicopathological analysis of 4 cases. *Zhonghua bing li xue za zhi= Chin J Pathol.* (2024) 53:1024–6. doi: 10.3760/cma.j.cn112151-20240311-00159

43. Sato S, Koike T, Homma K, Yokoyama A. Ciliated muconodular papillary tumor of the lung: a newly defined low-grade Malignant tumor. *Interactive Cardiovasc Thorac Surg.* (2010) 11:685–7. doi: 10.1510/icvts.2009.229989